drugset
drugset / Trial / NCT02214940

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers

NCT02214940 ↗

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

First evaluation of safety, tolerability, pharmacokinetics, and the pharmacodynamic effect of BI 11634 on coagulation parameters after multiple-dose administration (no primary endpoint in a statistical sense defined)

Timeline

Start
2007-06
Primary completion
2007-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 11634 Unknown 2.5 mg Oral
Subject BI 11634 Unknown 5 mg Oral
Subject BI 11634 Unknown 7.5 mg Oral
Subject BI 11634 Unknown 10 mg Oral

Indications

No indication recorded.